Approximately 97% of first-line patients experienced adverse reactions; the most commonly reported reactions in first-line patients usually occurred in the first week of therapy.
Umbes 97% - l esmakordselt ravi saavatest patsientidest tekkisid kõrvaltoimed; kõige enam esines esmakordselt ravi saavatel patsientidel kõrvaltoimeid esimese ravinädala jooksul.